OpenLegislation

Division 3.1.3.6.2.1 Where an ATE is not available for an individual ingredient of the mixture, but available information, such as that listed below, can provide a derived conversion value such as those laid out in Table 3.1.2, the formula in section 3.1.3.6.1 shall be applied.

United Kingdom

Original text. Later amendments are not shown.

This includes evaluation of:

  1. (a)

    extrapolation between oral, dermal and inhalation acute toxicity estimatesf1. Such an evaluation could require appropriate pharmacodynamic and pharmacokinetic data;

  2. (b)

    evidence from human exposure that indicates toxic effects but does not provide lethal dose data;

  3. (c)

    evidence from any other toxicity tests/assays available on the substance that indicates toxic acute effects but does not necessarily provide lethal dose data; or

  4. (d)

    data from closely analogous substances using structure/activity relationships.

This approach generally requires substantial supplemental technical information, and a highly trained and experienced expert (expert judgement, see section 1.1.1), to reliably estimate acute toxicity. If such information is not available, proceed to paragraph 3.1.3.6.2.3.

Annotations

Footnotes

f1

When mixtures contain components that do not have acute toxicity data for each route of exposure, acute toxicity estimates may be extrapolated from the available data and applied to the appropriate routes (see section 3.1.3.2). However, specific legislation may require testing for a specific route. In those cases, classification shall be performed for that route based upon the legal requirements.

Notes on Division 3.1.3.6.2

Textual amendments

F1

Substituted by Commission Regulation (EU) No 286/2011 of 10 March 2011 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance).